Welcome to
Chemical Collective

Are you 18 or older?

Please confirm that your are 18 years of age or older.

You are not allowed to access the page.

I am 18+

EXIT

SALE NOW ON!

PSYCH NEWS – 25/08/2025

By David Blackbourn

DEA Prompts Scientific Review of Psilocybin Rescheduling
GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant Depression
Enveric Biosciences’ Neuroplastogens
Aphantasia and Psychedelics
Flashbacks and Psychedelic Therapy
Bryan Johnson, Biohacking, and 5-MeO-DMT
Is the Trip Necessary for Psychedelics’ Therapeutic Effects?
Psychedelics and Postpartum Depression
Polypharmacology of Psychedelics

10 minute read

0 Last updated August 26th, 2025

By David Blackbourn

Disclaimer: The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Chemical Collective or any associated parties.

It has been another particularly busy couple of weeks in the world of psychedelics. We have seen landmark regulatory shifts in the US with the potential to reshape the future of research into psilocybin, a flurry of promising, potentially groundbreaking studies and clinical trials, and some extremely interesting deep dives into the fundamentals of the psychedelic experience.

DEA Prompts Scientific Review of Psilocybin Rescheduling

The US Drug Enforcement Agency (DEA) has formally directed the Department of Health and Human Services (HHS) to begin a scientific and medical review of the active ingredient in magic mushrooms. This action is in direct response to a rescheduling petition (activism can indeed work). This is the first-ever such request that has been prompted by the DEA. It is the first step towards potentially reclassifying the substance from Schedule I to something more conducive to continuing research efforts and therapeutic uses. The review by the HHS is a mandatory step prior to the DEA coming to any definitive conclusions about a potential rescheduling.

This push for change has been publicly applauded by a number of prominent companies in the sector. Red Light Holland, for example, highlighted the potential for rescheduling to open up many new avenues for both compassionate usage of the substance, as well as broader research potential. Red Light Holland has already imported natural psilocybin containing truffles from the Netherlands to a DEA lab in the US. Reclassifying psilocybin would be a crucial step towards FDA approval for the growing number of potential therapeutic applications of the substance, combating conditions such as depression and anxiety, and PTSD, particularly among the veteran and first-responder communities.

GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant Depression

GH Research PLC has recently announced some positive data from its Phase-2B trial of the substance GH001. GH001 is a unique, inhalable formulation of mebufotenin, which is commonly known as 5-MeO-DMT. The results are promising, and the data illustrate 5-MeO-DMT’s success in improving symptoms of treatment-resistant depression (TRD). After just eight days, the new treatment caused a significant reduction in symptoms of TRD when compared to a placebo.

On a standard depression scale, patients who were administered the active substance improved by 15.5 points more than those who received the placebo. By day eight, more than half of the participants who had been given 5-MeO-DMT (57.5%) had a complete reduction of their symptoms. In the placebo group? Zero.

The results were not only positive in terms of final outcome, though. The treatment was well tolerated by all who received it. All adverse reactions were reported to be mild or moderate, and no serious complications or events occurred throughout the study. When their vital signs were measured, there were no significant changes. On completion of the study, discharged individuals also had no dissociative symptoms or sedation. This is in pretty stark contrast to our current means for tackling TRD, which can come with a raft of potentially very dangerous side effects.

The rapid onset and conclusion of the effects, and seemingly excellent safety profile of the substance, were further highlighted, as 97.4% of patients were able to leave the clinic a single hour after their final dose. This shows just how effective and scalable this treatment model could be in the future.

Enveric Biosciences’ Neuroplastogens

Enveric Biosciences is a prominent company in the ever-evolving landscape of psychedelic medicine. They are differentiating themselves from the majority of others in the space by focusing on non-hallucinogenic alternatives to traditional psychedelics. These are known as neuroplastogens. The company are developing novel molecules which share some common features with classic hallucinogens without inducing the often long-lasting and potentially difficult to manage consciousness-altering effects. Neuroplastogens (as their name may suggest) are engineered to promote neuroplasticity, which is the brain’s ability to change and rewire itself.

This approach bypasses the majority of the legal hurdles still blighting psychedelic research the world over, as well as avoiding the extremely significant time/resource issue associated with psychedelic use in a therapeutic context. The aim is to take what we have already learned from the way psychedelics appear to affect the brain, and apply this to novel chemicals which are more easily scalable and accessible.

The current best-placed compound thus far is EB-003, which is a substance that has already shown great promise in tackling the debilitating effects of PTSD. In animal models, EB-003 demonstrated powerful therapeutic responses, equivalent to MDMA but with zero signs of hallucinations, euphoria, etc. In fact, no changes in consciousness were experienced by all who were administered the substance.

Their focus solely on non-psychoactive compounds is allowing the company to explore novel therapeutic mechanisms that psychedelics promote, while potentially providing a more predictable and controllable clinical experience for the patients themselves. (Not everyone wants to talk to God to cure their depression after all.)

Enveric has developed what they have named their Psybrary platform, a powerful portfolio of unique substances, developed in-house, with unique receptor binding profiles and pharmacokinetic properties. They are in the process of out-licensing Psybrary assets, with EB-003 still available for partnering.

Aphantasia and Psychedelics

An article published in the journal Cortex from researchers at the University of New South Wales (UNSW Sydney) and Macquarie University has urged caution for individuals with aphantasia seeking psychedelic therapy. Aphantasia is a condition that is characterised by the inability to form voluntary mental images. The warning itself is in response to a growing number of anecdotal reports and case studies reporting odd, immediate effects. People with aphantasia are experiencing a sudden, complete remission of their symptoms. After a single dose of a psychedelic like psilocybin or ayahuasca, they immediately gain the ability to consciously visualise. While the majority of the reports of these occurrences are overwhelmingly positive, rapid brain changes are not to be accepted without careful study. Suddenly “opening the mind’s eye” may come with some potential risks.

The most concerning part of this newfound ability to create visual imagery is that it could open the door to intrusive and potentially extremely distressing thoughts and images. The lack of familiarity with the experience of imagery in this way may make individuals with aphantasia especially prone to these negative effects. The authors of the article cite the large body of research linking PTSD flashbacks, depressive rumination on perceived future negative events, and addiction cravings directly with strong, vivid imagery. People with aphantasia are far less likely to experience these issues, so the sudden onset of the ability to produce visuals could be severely jarring and psychologically difficult. The authors further stress the ethical necessity to include aphantasia in the informed consent process leading up to psychedelic therapy.

The article speculates that it is the neuroplastic effects of psychedelics which are causing these dramatic changes in individuals’ capacity. Neuroplasticity is believed to be driven by the activation of 5-HT2A receptors in the brain, which are the primary target of classic psychedelics. Psychedelics are known to increase connectivity between parts of the brain that do not usually communicate with one another. This, it is surmised, may be the means by which aphantasia is immediately bypassed. The neural pathways affected by aphantasia (those that involve visual processing, memory, higher order thought) could potentially be reconfigured by psychedelics. While this does come with some definite therapeutic potential – as we can see from the many positive reports of individuals who have experienced the change – the risks are not insubstantial. Making sure anyone undergoing a course of psychedelic therapy is aware of these potential effects is necessary to ensure their decision to undergo treatment is sufficiently informed.

Flashbacks and Psychedelic Therapy

A Psychology Today article, authored by Gary L. Wenk (Ohio State University), discusses another important element of the informed consent of individuals seeking psychedelic therapy. The phenomenon of flashbacks. Flashbacks, in this context, are defined as “the recurrence of, or recurring drug-like experiences after the acute substance effects have worn off”. These are not uncommon. LSD-induced flashbacks were regularly reported throughout the 1950s when LSD was first applied as an adjunct to therapy. While culturally LSD is the psychedelic most commonly associated with flashbacks (acid-flashbacks), they are not exclusive and have been reported with a variety of substances. The official DSM-5 (The Diagnostic and Statistical Manual of Mental Disorders) reports that roughly one in 25 users of psychedelics will experience flashbacks. When considering just how many people consume psychedelics, this is a significant number.

The flashbacks themselves are usually visual in nature, but can also be accompanied by feelings of depersonalisation or rapid shifts in mood. A recent review of clinical trials involving psychedelics showed that about 10% of participants were affected by flashbacks. However, importantly, only a tiny fraction of these individuals characterised the flashbacks as negative experiences. This is encouraging as it suggests that while popular culture may portray the acid flashback as a horrifying ordeal, this may well not be the case for the vast majority of people.

Once again, neuroplasticity is believed to be the cause of these effects. As powerful psychedelic experiences are so vivid and unique to the individual that the brain can create intense, involuntary memories as a result. These memories can then spontaneously trigger at a later date. Oddly enough, the psychiatric challenges which psychedelics are increasingly seen to tackle (anxiety, PTSD) can, in fact, be risk factors for those experiencing potentially distressing flashbacks. This just further underlines the complexity of both the brain itself and psychedelics’ effects on it, and the necessity for further study, and in the meantime, solid guidelines for their use.

Bryan Johnson, Biohacking, and 5-MeO-DMT

Bryan Johnson is a tech multimillionaire who is famous for developing what he calls “Project Blueprint” – a radical approach to longevity. Johnson’s goal is to actively reverse the ageing process, and he is spending millions of dollars each year in hopes of achieving the goal. He is known for his extremely (at least reportedly, grain of salt etc.) meticulous and data-driven approach to health. His daily regimen involves an entire team of doctors, over 100 pills, and an intensely restricted diet. Johnson has recently spoken about another frontier he is attempting to investigate – human consciousness. He is attempting to engage in what he describes as a systematic exploration of different mental states. To do so, he is taking 5-MeO-DMT, adding an extremely powerful psychedelic to his exhaustive daily regimen.

Johnson described 5-MeO-DMT’s ability to produce an “expansive map of human consciousness”, opening up dimensions he was previously completely unaware of. Rather than a sidenote, his usage of 5-MeO-DMT was a deliberate part of his quest for ultimate optimisation of the human body – stressing the importance of the mind as well.

Johnson framed his psychedelic experience as a part of one of humanity’s greatest remaining challenges. He asked why humans are not as excited about exploring consciousness as they are about developing artificial superintelligence or going to Mars. Exploring inner space as opposed to seeking external goals is a completely different area of expertise. Johnson considers consciousness to be the “gold mine of our very existence.” Humanity’s ultimate resource.

While his methods are controversial (personally, I am far from convinced), the fact that he has a rapidly increasing platform to illustrate his integration of psychedelics into his anti-ageing protocol is powerful. True longevity, perhaps, is not just about simply extending the body’s lifespan; it is also about expanding our consciousness and opening up the as-yet-unexplored frontiers of the mind.

Is the Trip Necessary for Psychedelics’ Therapeutic Effects?

One of the most pressing questions in psychedelic science. Is the psychedelic “trip” essential for their mental health benefits? A recent primer in NPP – Digital Psychiatry and Neuroscience tackles this question head-on. The article deconstructs the traditional narrative that the profound, consciousness-altering effects, even transcendent experiences, are the primary driver for their healing properties. While acknowledging that mystical experiences, or effects like ego death, are confirmed to correlate with positive outcomes for users, this relationship is far from absolute, varying significantly depending on the substance.

The paper presents a more nuanced view, analysing the available statistical data, rather than relying on anecdotal accounts. For psilocybin, the subjective experience, the “trip”, seems to be a strong predictor – accounting for roughly 24% of the variance in therapeutic outcomes. For ketamine, however, the link is far less pronounced, with subjective effects only predicting around 5-10% of the perceived benefits. For MDMA, there is, in fact, no statistically significant relationship between the intensity of the individual experience and its long-term success in treating PTSD. This variance between chemicals suggests that in some contexts the “trip” may be important, but there are obviously other mechanisms at play.

An increasingly popular theory is that the therapeutic benefits are derived from biology rather than psychology. Once again, neuroplasticity is seen to be key, as well as the anti-inflammatory effects of a particular substance, as opposed to the experience itself. This links back into the research we previously discussed on non-psychoactive compounds, which may mirror the benefits of traditional psychedelics. The ultimate goal of these attempts is to properly and accurately assess how relevant the psychedelic experience really is to healing. Is it a profound side-effect that can be engineered out in future, or will we lose the true power of these substances in our efforts to blunt their immediate psychological impact?

Psychedelics and Postpartum Depression

In potential life-changing news for people suffering from post-partum depression (PPD), Reunion Neuroscience has reported positive results from its Phase 2 study of its proprietary psychedelic-inspired compound, RE104. RE104 is a prodrug of 4-OH-DIPT, a synthetic tryptamine with effects similar to psilocybin, but built specifically to have a much shorter duration. This reduces the most intense part of the trip to under four hours, roughly half that of a normal psilocybin experience. This key feature is designed to make the therapy much more practical to carry out in clinical settings, and for new mothers, who could potentially return to breastfeeding soon after treatment.

The trial successfully met its initial goal, with RE104 demonstrating rapid effectiveness and a significant reduction in symptoms of PPD. Patients completed Montgomery-Asberg Depression Rating Scale (MADRS) assessments to ascertain the effectiveness of the experience. 77.1% of all patients who received a therapeutic dose showed at least a 50% improvement in their depression scores by day seven. This is compared with 61.6% in the control group. In fact, 71.4% of patients in the treatment group actually entered remission – remission being defined as a MADRS score of 10 or less – which was a substantially higher rate of remission than the 41% observed in the control group. The positive effects were also sustained up to the patients’ 28-day follow-up.

These extremely significant results hold so much promise for those struggling with such a difficult, debilitating condition. Reunion Neuroscience is pushing to advance RE104 to Phase 3 Trials in 2026. RE104 is also entering Phase 2 of a study of its effectiveness in treating adjustment disorder in patients with cancer.

Polypharmacology of Psychedelics

A major new study, published in Neuron in late July 2025, has mapped the specific molecular activity of 41 different psychedelic substances. They have, perhaps unsurprisingly, uncovered a far more complicated picture than previously thought.

While it is widely understood that the majority of psychedelics’ main area of activity is the 5-HT2A receptor. This new research counters this idea. By studying tryptamines, phenethylamines, and lysergamides against literally hundreds of human receptors, researchers have found these compounds to have powerful effects at nearly every receptor they tested. That’s every serotonin, dopamine, and adrenergic receptor in the body. They describe this as “polypharmacology”. These findings help explain why psychedelics can influence such a wide array of bodily processes and have such varied, vivid, and lasting effects.

The study also uncovered a potential safety concern, as all 41 psychedelics which were tested were seen to activate the 5-HT2B receptor. Sustained activation of this particular serotonin receptor has been linked to issues with heart disease. This suggests complications with sustained usage of any of these substances. This is vital knowledge when determining what psychedelics to use and how to dose them in the future. For example, would microdosing a substance potentially hold risk if the slight, but sustained activation of 5-HT2B was continued for a period of time? This research underlines the need to better understand the specific molecular targets that elicit the particular desired therapeutic outcome. As always, further study is required.

David Blackbourn | Community Blogger at Chemical Collective

David is one of our community bloggers here at Chemical Collective. If you’re interested in joining our blogging team and getting paid to write about subjects you’re passionate about, please reach out to Sam via email at samwoolfe@gmail.com

share your toughts

Join the Conversation.

0 Comments

Inline Feedbacks

View all comments

9 minute read

In his book The Weird and the Eerie, cultural theorist Mark Fisher analyses the concept of the 'weird'. Sam Woolfe applies Fisher's analysis to psychedelic states.

09 Feb, 2026

Opinion | Psychedelics and Mark Fisher’s Theory of the Weird

Sam Woolfe

13 minute read

Un aperçu objectif du protoxyde d'azote, examinant sa normalisation croissante, ses effets puissants, son attrait, ses risques et son histoire.

07 Feb, 2026

Guides | Le gaz hilarant : Le protoxyde d’azote (N2O)

Nuit

13 minute read

Nuit compare les expériences de LSA issues de deux sources de semences, contextualisées par l'histoire et la science, dans le but de présenter une vision équilibrée des effets variables, des incertitudes, des risques et des enseignements de la LSA.

05 Feb, 2026

Personal Stories | Le LSA : la version naturelle du LSD ?

Nuit

12 minute read

Stroke, traumatic brain injury, and neurodegenerative diseases are leading, interconnected causes of global disability and economic burden with limited effective treatments. Sam Gandy highlights the potential of psychedelics as novel therapies to promote brain repair and recovery.

03 Feb, 2026

Science | Can Psychedelics Help Mend Broken and Ailing Brains?

Sam Gandy

11 minute read

The ancient, subterranean networks of fungi underpin life on Earth and are now emerging as a powerful foundation for future sustainable biotechnologies.

01 Feb, 2026

Science | Beyond the Trip: How Fungi Are Engineering Our Future

David Blackbourn

8 minute read

Dans la deuxième partie de ce guide sur l'influence du dosage sur les expériences psychédéliques, Eliacide examine les combinaisons de drogues et les expériences qui ne visent pas à dissoudre l'ego.

30 Jan, 2026

Guides | L’influence du dosage sur les expériences psychédéliques (Partie 2)

Eliacide

9 minute read

Eliacide explique que le dosage des médicaments est très subjectif et doit être choisi en fonction du niveau d'expérience personnel et du contexte souhaité, avertissant que les débutants doivent éviter les doses élevées et encourageant les individus à trouver leur propre « juste milieu » plutôt que de considérer tout conseil comme absolu.

28 Jan, 2026

Guides | L’influence du dosage sur les expériences psychédéliques (Partie 1)

Eliacide

9 minute read

Real-world data confirms the extremely low physical risk of psychedelics; the NHS and FDA intensify their scrutiny of clinical rollout; and we see expanding legal momentum in the US, as well as a shift towards shorter-acting compounds and even non-hallucinogenic, virtual alternatives.

26 Jan, 2026

All Articles | PSYCH NEWS – 26/01/2026

David Blackbourn

12 minute read

Nuit s'entretient avec Andrés Gómez, chercheur en conscience à l'Institut de recherche Qualia, qui fait le lien entre la science informatique, les récits expérientiels, les traditions contemplatives orientales et la recherche psychédélique.

25 Jan, 2026

Personal Stories | Mon échange avec le chercheur Andrés Gómez Emilson

Nuit

10 minute read

John Robertson offers a practical guide to understanding the causes of non-responses to psychedelics and what to do to move beyond them safely and effectively.

24 Jan, 2026

Guides | The ‘Nada’ Experience: What To Do When Psychedelics Don’t Work (Part 2)

John Robertson

7 minute read

Alfredo Squillaro argues that informed use, drug checking, and education are far more effective than stigma and repression in reducing the risks of psychoactive substance use.

22 Jan, 2026

Opinion | (Anti)prohibition, Psychonautics, and Designer Drugs

Alfredo Squillaro

11 minute read

Oli Genn-Bash reflects on the Western pursuit of an “authentic self,” using personal psychedelic experiences to question whether self-discovery is less about uncovering a fixed identity and more about cultivating a healthy relationship with the self that allows it to soften, open, and connect with others.

20 Jan, 2026

Self-Development | Discovering the Authentic Self Through Psychedelics

Oli Genn-Bash

9 minute read

Free parties can be understood as modern expressions of ancient ritual practices – akin to the Dionysian Mysteries – where music, dance, and psychoactive substances induce ecstatic states of consciousness.

18 Jan, 2026

Opinion | Dionysian Cults and Free Parties

Alfredo Squillaro

13 minute read

Nuit décrit son expérience du 2C-P comme un psychédélique puissant, à action lente et prolongée, appartenant à la famille des 2C-x – davantage comparable à une longue et exigeante randonnée qu'à un simple voyage.

16 Jan, 2026

Personal Stories | 2C-P : La charrette psychédélique

Nuit

11 minute read

Can psychedelics genuinely challenge and undermine the military-industrial complex by transforming consciousness, or do they risk being co-opted to merely help individuals psychologically adapt to an inherently violent and unjust system?

14 Jan, 2026

Opinion | Decentralised Minds: Can Psychedelics Undermine the Military Industrial Complex?

Oli Genn-Bash

11 minute read

Oli Genn-Bash explores the growing popularity of functional mushrooms, blending personal experience, research, and traditional perspectives to argue for a more holistic, respectful understanding of fungi.

12 Jan, 2026

Opinion | A Holistic and Spiritual Approach to Functional Mushrooms

Oli Genn-Bash

11 minute read

Despite bold promises surrounding psychedelics, a significant share of patients fail to meaningfully improve, revealing that non-response is a central – and often overlooked – challenge in psychedelic therapy.

10 Jan, 2026

Science | Let’s Talk About Non-Responders in Psychedelic Therapy

Ed Prideaux

8 minute read

Psychedelic use is commonly divided into spiritual, therapeutic, and recreational categories whose meanings are unclear and unevenly valued, with recreational use often stigmatised despite having aspects that deserve reconsideration.

08 Jan, 2026

Opinion | In Defence of Recreational Psychedelic Use

Annabelle Abraham

15 minute read

The Immortality Key builds a sweeping psychedelic-religion narrative on evidence that its own primary scientific authority later rejected as methodologically flawed, undermining the book’s credibility despite its popular success.

06 Jan, 2026

History | Psychedelic Bullshit? An Evaluation of The Immortality Key

Ed Prideaux

10 minute read

Over the past year, the psychedelic field has seen unprecedented scientific and regulatory advances collide with bureaucratic barriers and venture capital pressures, revealing both rapid progress toward medical integration and the fragility – and cultural tension – of an emerging industry at a pivotal moment.

04 Jan, 2026

News & Updates | PSYCH NEWS 2025 – THE YEAR IN REVIEW

David Blackbourn

8 minute read

Martha Allitt unpacks the history of MK-ULTRA, a secret CIA program that conducted unethical experiments with LSD, hypnosis, and other techniques in an attempt to develop methods of mind control and psychological manipulation during the Cold War.

04 Jan, 2026

History | MK-ULTRA: A Macabre History of LSD and Mind Control

Martha Allitt

16 minute read

Ed Prideaux examines Elon Musk’s alleged drug use and public behaviour in the context of his immense political and technological influence.

02 Jan, 2026

Opinion | High on Power: How Much Does Ketamine Explain Elon Musk’s Erratic Behaviour?

Ed Prideaux

10 minute read

Psychedelics can help us rethink the “hard problem” of consciousness by challenging the materialist view that the brain generates experience.

30 Dec, 2025

Philosophy | Psychedelics and the Hard Problem of Consciousness

David Blackbourn

12 minute read

Nuit décrit le 2C-C comme un membre subtil et apaisant de la famille 2C-X, qui évoque de doux souvenirs d'expériences sereines et introspectives.

28 Dec, 2025

Guides | 2C-C : la version Stone du 2C-B ?

Nuit

4 minute read

Theories suggest that N,N-dimethyltryptamine (DMT) is released in our brains when we die – but what do we really know about this potent psychedelic and its endogenous role in the human body?

22 Dec, 2025

Science | The Endogenous DMT Narrative: Separating Fact From Fiction

Stephanie Price

11 minute read

While psychedelics get most of the limelight in discussions about altered states of consciousness, such states can also be accessed through more accessible and potentially safer means, particularly sound baths.

20 Dec, 2025

Spirituality | Sound Baths and Altered States

Oli Genn-Bash

9 minute read

David Blackbourn explores the history and present-day use of psychoactive substances in the Middle East, including the religious, social, and political factors that have influenced this usage.

18 Dec, 2025

History | Contemporary Psychoactive Drug Use in the Middle East

David Blackbourn

8 minute read

Iboga, a West African shrub traditionally used in the Bwiti spiritual tradition, is now being used for microdosing in the West.

16 Dec, 2025

Personal Stories | Microdosing Iboga: Why People Are Taking Tiny Amounts of a Hallucinogenic Shrub

Martha Allitt

5 minute read

Clinical trials typically evaluate psychedelics through short-term before-and-after measures to assess treatment efficacy, but longer-term and lifelong effects are harder to quantify.

14 Dec, 2025

Self-Development | The Long-Term Effects of Psychedelics Are Sometimes Ambiguous

Annabelle Abraham

11 minute read

While psychedelic insights may be valuable, they can be difficult to interpret and require a broader psychological, spiritual, philosophical, or cultural framework to determine whether they reflect genuine truth or mere subjective experience.

12 Dec, 2025

Self-Development | Psychedelics and Epistemic Authority: How Can We Trust Psychedelic Insights?

Oli Genn-Bash

Our Products

Related Products

SALE! -35%

1V-LSD 150mcg Blotters From

(145)

1cP-LSD 100mcg Blotters From 18.00

(137)

Tryptamine Mix and Match Pack (4 x 0.1g) €65.00

(1)

SALE! -35%

1V-LSD 10mcg Micro Pellets From

(44)

SALE! -35%

1V-LSD 225mcg Art Design Blotters From

(62)

1S-LSD 150mcg Blotters From 29.00

(18)

1cP-LSD 150mcg Art Design Blotters From 25.00

(74)

SALE! -35%

1V-LSD 225mcg Pellets From

(26)

1cP-LSD 10mcg Micro Pellets From 15.00

(23)

1D-LSD 225mcg Pellets (1T-LSD) From 42.00

(13)

5-MeO-DMT Freebase From 23.95

(36)

1S-LSD 10mcg Micro Pellets €20.00

(3)

O-PCE HCL From 17.50

(25)

1cP-LSD 20mcg Micro Blotters From 18.00

(28)

1cP-LSD 150mcg Pellets From 25.00

(13)

see all products

Earn
Affiliates

Welcome to Chemical Collective.

Create an account to earn 200 welcome points.

create account

Already have an account? Sign in

Comment on an article

50

Check out our Community Blog and get involved with the conversation. You will be awarded 50 x ChemCoins for each comment up to a limit of 250 total ChemCoins.
Leave a product review

50

Have you purchased any of our products? Reviews and reports are so important to the community. Share your honest opinion, and we’ll reward you with 50 ChemCoins for each review!
Complete an order

X

Every time you complete an order with us, you’ll be awarded ChemCoins for each Euro spent.

Welcome to Chemical Collective.

Create an account to earn 200 welcome points.

create account

Already have an account? Sign in

Become an affiliate!

Earn commission every time someone makes a purchase through your link.

When you become an affiliate, you will be allocated a unique link to share with your friends, followers, subscribers, or Aunt Susan.

You can choose to payout the commission earned once per month, or save it up to receive on a rainy day! Commission earned is 5% of the total order value per referral.

Contact us to join the Chemical Collective family and become an affiliate.

Welcome toChemical Collective

PSYCH NEWS – 25/08/2025

By David Blackbourn

in this article

By David Blackbourn

DEA Prompts Scientific Review of Psilocybin Rescheduling

GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant Depression

Enveric Biosciences’ Neuroplastogens

Aphantasia and Psychedelics

Flashbacks and Psychedelic Therapy

Bryan Johnson, Biohacking, and 5-MeO-DMT

Is the Trip Necessary for Psychedelics’ Therapeutic Effects?

Psychedelics and Postpartum Depression

Polypharmacology of Psychedelics

By David Blackbourn

share your toughts

Join the Conversation.

Related articles

Related Products

Reward program

Comment on an article

Leave a product review

Complete an order

Become an affiliate!

Welcome to
Chemical Collective